Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy
We evaluated intramuscular (IM) versus intravenous (IV) administration of tixagevimab/cilgavimab in early COVID-19. Both routes achieved rapid elimination of culturable virus and minimal emergence of resistance. These results support IM delivery as a viable alternative to IV, with important implications for scalable deployment in future viral pandemics.
Authors
- William A. Fischer (ORCID: https://orcid.org/0000-0002-4900-098X)
- Karina Soboleva
- Kara W Chew (ORCID: https://orcid.org/0000-0003-4865-4348)
- Rinki Deo
- Rachel Bender Ignacio (ORCID: https://orcid.org/0000-0001-6167-1447)
- Courtney Vail Fletcher (ORCID: https://orcid.org/0000-0002-3703-7849)
- Evgenia Aga
- Joseph J. Eron (ORCID: https://orcid.org/0000-0002-4938-0644)
- Carlee Moser (ORCID: https://orcid.org/0000-0001-5601-9112)
- Taylor S. Cohen (ORCID: https://orcid.org/0000-0001-9368-0903)
- Arzhang Cyrus Javan
- Jonathan Z. Li (ORCID: https://orcid.org/0000-0001-9914-9662)
- Davey M. Smith (ORCID: https://orcid.org/0000-0003-3603-1733)
- Amy K. Barczak (ORCID: https://orcid.org/0000-0003-3806-2381)
- Robert W. Coombs (ORCID: https://orcid.org/0000-0003-2709-0512)
- David A. Wohl (ORCID: https://orcid.org/0000-0002-7764-0212)
- Alexander L. Greninger (ORCID: https://orcid.org/0000-0002-7443-0527)
- M.R.J. Gibbs (ORCID: https://orcid.org/0000-0003-1978-3378)
- Julie Boucau (ORCID: https://orcid.org/0000-0001-6731-7238)
- Eric S. Daar (ORCID: https://orcid.org/0000-0003-1880-7331)
- Katie L. Streicher (ORCID: https://orcid.org/0000-0003-1684-2301)
- Mark J Giganti (ORCID: https://orcid.org/0000-0003-2255-9756)
- Judith S. Currier (ORCID: https://orcid.org/0000-0003-4279-4737)
- Owen T. Glover
- Michael D. Hughes (ORCID: https://orcid.org/0000-0001-8562-2316)
- Manish C Choudhary
Institutions
- Brigham and Women's Hospital (US)
- National Institutes of Health (US)
- University of North Carolina Health Care (US)
- Harvard University (US)
- University of San Diego (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- UCLA Medical Center (US)
- Ragon Institute of MGH, MIT and Harvard (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (France) (FR)
- AstraZeneca (Finland) (FI)
- Harbor–UCLA Medical Center (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1093/ofid/ofaf542
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- ViiV Healthcare
- National Institutes of Health